CP-690550 citrate

• CAT Number: A000284
• CAS Number: 540737-29-9
• Molecular Formula: C₁₆H₂₀N₆O.C₆H₈O₇
• Molecular Weight: 504.49
• Purity: ≥95%
• Target: JAK
• Solubility: >25.2mg/mL in DMSO
• Storage: 3 years -20C powder
• IUPAC Name: 2-hydroxypropane-1,2,3-tricarboxylic acid;3-[(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanenitrile
• InChI: InChI=1S/C16H20N6O.C6H8O7/c1-11-5-8-22(14(23)3-6-17)9-13(11)21(2)16-12-4-7-18-15(12)19-10-20-16;7-3(8)1-6(13,5(11)12)2-4(9)10/h4,7,10-11,13H,3,5,8-9H2,1-2H3,(H,18,19,20);13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/t11-,13+;/m1./s1
• InChIKey: SYIKUFDOYJFGBQ-YLAFAASESA-N
• SMILES: C[C@@H]1CCN(C[C@@H]1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O

CP-690550 citrate（Cat No.:A000284）is a selective inhibitor of Janus kinase 3 (JAK3), an enzyme involved in cytokine signaling and immune cell function. By inhibiting JAK3, CP-690550 modulates the immune response, making it a potential therapeutic agent for autoimmune diseases and inflammatory conditions. This compound has shown significant efficacy in preclinical and clinical studies, particularly for conditions like rheumatoid arthritis and organ transplant rejection. Its ability to selectively target JAK3 over other JAK family members enhances its therapeutic profile, minimizing off-target effects. CP-690550 citrate represents a promising approach in the treatment of immune-mediated disorders.